An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Mohamed L. Sorror(University of Washington Medical Center), Elihu H. Estey(University of Washington), Lynn Onstad(Fred Hutch Cancer Center), Aaron T. Gerds(Cleveland Clinic), Ted Gooley(Fred Hutch Cancer Center), Jeannine S. McCune(City of Hope), Stephanie J. Lee(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Tammy A. Schuler(Fred Hutch Cancer Center), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Mitchell Garrison(Wenatchee Valley Hospital & Clinics), Maria R. Baer(University of Maryland, Baltimore), Pamela S. Becker(City Of Hope National Medical Center), Jamie Koprivnikar(Hackensack University Medical Center), Mikkael A. Sekeres(University of Miami), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David A. Rizzieri(Duke University), Wendy M. Leisenring(The University of Texas MD Anderson Cancer Center), Barry E. Storer(City Of Hope National Medical Center), Kehinde Adekola(Northwestern Memorial Hospital), Kiarash Kojouri(Skagit Valley Hospital), Tanya M. Wildes(University of Nebraska Medical Center), Brenda M. Sandmaier(University of Washington), Paul J. Shami(University of Utah), Bruno C. Medeiros(Stanford Medicine), Julie Smith(University of Strathclyde), Selina M. Luger(University of Pennsylvania)
Blood
October 19, 2022
Cited by 33


Related Papers